Sixth, sarcopenic evaluation by BIA is not seemed to be cost-effective just for the cystatin C indication, but BIA could be utilized due to their increasing use in hospitalized patients for sarcopenia, frailty or nutritional assessment. The gene discussed is CST3; the disease is sarcopenia.